Immunotherapeutic targeting of aging‐associated isoDGR motif in chronic lung inflammation

Pazhanichamy Kalailingam, SoFong Cam Ngan, Ranjith Iyappan, Afra Nehchiri, Khalilatul‐Hanisah Mohd‐Kahliab, Benjamin Sian Teck Lee, Bhargy Sharma, Radek Macháň, Sint Thida Bo, Emma S. Chambers, Val A. Fajardo, Rebecca E. K. MacPherson, Jian Liu, Panagiota Klentrou, Evangelia Tsiani, Kah‐Leong Lim, I-hsin Su, Yong‐Gui Gao, A. Mark Richar, Raj N. Kalaria, Christopher Chen, Cynthia Balion, Dominique P.v. de Kleijn, Neil E. McCarthy, Siu Kwan SzeAging 2025 · DOI

TL;DR

This study reveals that a specific protein modification, the isoDGR motif, accumulates with age in lung tissue and drives chronic inflammation and age-related lung diseases. Importantly, an antibody targeting this motif effectively clears the damaged proteins, reduces inflammation, and improves lung function in aged and genetically modified mice, offering a promising therapeutic avenue for age-related lung conditions.

What Problem Does This Paper Address?

Aging is fundamentally linked to the accumulation of molecular damage within our tissues, a process that contributes to chronic diseases and overall decline. A significant challenge is that many of these damages, particularly spontaneous protein modifications, have been considered untreatable because traditional gene or enzyme-targeting therapies are ineffective. One such modification is the isoDGR motif, which arises from the deamidation of the NGR sequence in extracellular matrix proteins. This isoDGR motif can bind to integrins on immune cells, triggering inflammation. While previous work hinted at its role in aging and vascular inflammation, its specific contribution to age-related lung pathology and its therapeutic potential remained unclear. This paper aims to elucidate the role of isoDGR in chronic lung inflammation and aging, and to investigate whether targeting it with an antibody can ameliorate these age-associated pathologies.

Methods

The researchers employed a multi-pronged approach to investigate the role of isoDGR in lung aging and inflammation:

  • Immunohistochemistry and Tissue Microarrays: They used human lung tissue microarrays from individuals of varying ages and with pulmonary fibrosis to visualize and quantify isoDGR protein levels and immune cell infiltration (CD68+ and CD11b+ macrophages).
  • Animal Models: They utilized naturally aged mice and mice genetically engineered to lack the isoDGR repair enzyme (Pcmt1-/- mice) to study the in vivo effects of isoDGR accumulation.
  • Molecular and Cellular Assays:
    • Western Blotting: To confirm protein levels of Pcmt1 and isoDGR.
  • SpO2 Assay: To measure blood oxygen saturation and assess hypoxemia.
  • Evans Blue Assay: To evaluate vascular permeability and pulmonary edema.
  • Bronchoalveolar Lavage (BAL) and Cytokine Multiplex Bead Assay: To measure inflammatory cytokine levels in lung fluid.
  • RNA-sequencing (RNA-seq) and Single-cell RNA sequencing (scRNA-seq): To analyze global gene expression changes in lung tissue and to understand the cellular landscape and changes in different cell populations in response to isoDGR and antibody treatment.
  • Seahorse Assay and CellROX ROS Assay: To assess mitochondrial function and reactive oxygen species production.
  • SA-βgal and TUNEL Assays: To detect cellular senescence and apoptosis.
  • Immunotherapy: They administered a specific anti-isoDGR monoclonal antibody (mAb) to aged and Pcmt1-/- mice to assess its therapeutic efficacy.

Datasets

  • Human Lung Tissue Microarrays (TMAs): Two types of TMAs were used: TMA-LC2086a (192 sections of normal human lung tissues with varying age) and TMA-LC561 (56 sections of pulmonary interstitial fibrosis tissues, plus controls).
  • Mouse Lung Tissue: Tissues were collected from wild-type (WT) C57BL/6J mice (aged 17 months and naturally aged 18-26 months) and Pcmt1+/- and Pcmt1-/- mice (aged 6 weeks, 1.5 years, and 17 months).
  • RNA-seq Data: Data were generated from the lungs of Pcmt1+/+, Pcmt1+/-, Pcmt1-/-, and mAb-treated Pcmt1-/- mice. This data is deposited in GEO-NCBI (GSE224434).

Key Insights and Ideas

  • IsoDGR as a Driver of Age-Related Lung Disease: The study strongly implicates the isoDGR motif not just as a marker of aging but as an active contributor to lung pathology, driving inflammation, edema, and hypoxemia.
  • Targeting a "Damage Motif" is Feasible: This work demonstrates that a therapeutic strategy targeting a specific molecular "damage signature" (isoDGR) can be effective, overcoming the limitations of targeting genes or enzymes directly.
  • Immune Clearance as a Therapeutic Mechanism: The anti-isoDGR antibody works by facilitating the immune system's clearance of these damaged proteins, rather than directly repairing them.
  • IsoDGR's Multifaceted Impact: Beyond inflammation, isoDGR accumulation was found to disrupt mitochondrial function, ribosomal activity, and promote cellular senescence, highlighting its broad detrimental effects.
  • Cellular Landscape Shifts: scRNA-seq revealed significant alterations in immune cell populations (decreased B and NK cells, increased monocytes and dendritic cells) in Pcmt1-/- mice, which were partially reversed by mAb treatment, suggesting a role for these cells in isoDGR-mediated pathology.

Key Results

  • Age-Dependent IsoDGR Accumulation: IsoDGR levels were found to increase with age in human lung tissues, with an 8-fold enrichment in fibrotic areas.
  • Correlation with Immune Infiltration: IsoDGR levels positively correlated with the presence of CD68+ and CD11b+ macrophages in both human and mouse lung tissues.
  • Pcmt1-/- Mice Exhibit Severe Lung Pathology: These mice showed pulmonary edema, hypoxemia (reduced SpO2), impaired vascular permeability, and histological signs of emphysema.
  • Antibody Treatment Ameliorates Pathology: Treatment with anti-isoDGR mAb significantly reduced lung inflammation, edema, hypoxemia, and improved lung histology in Pcmt1-/- mice.
  • Restoration of Mitochondrial Function: The antibody treatment restored normal oxygen consumption and extracellular acidification rates in lung endothelial cells exposed to isoDGR-modified fibronectin.
  • Reduced Senescence and Apoptosis: mAb treatment decreased markers of cellular senescence (β-gal) and apoptosis (TUNEL) in Pcmt1-/- mouse lungs.
  • Transcriptomic Signatures Reversed: RNA-seq data showed that mAb treatment could restore the expression of many genes dysregulated in Pcmt1-/- mice, including those involved in TLR pathways and mitochondrial function.

Limitations and Future Work

  • Immune Response to Therapy: The authors acknowledge the possibility of immune responses arising with prolonged therapy, suggesting that further studies are needed to assess long-term safety and efficacy.
  • Broader Therapeutic Potential: While the study focused on lung pathology, the authors suggest that since isoDGR accumulates throughout the body, the anti-isoDGR mAb may have broader therapeutic applications beyond lung disease, warranting further investigation.
  • Mechanisms of Immune Clearance: While the study demonstrates immune clearance, further elucidation of the precise mechanisms by which the antibody facilitates this process would be beneficial.
  • Translational Studies: While promising, further studies are needed to translate these findings into clinical applications for human age-related lung diseases.

Summary updated

Abstract

Accumulation of damaged biomolecules in body tissues is the primary cause of aging and age-related chronic diseases. Since this damage often occurs spontaneously, it has traditionally been regarded as untreatable, with typical therapeutic strategies targeting genes or enzymes being ineffective in this domain. In this report, we demonstrate that an antibody targeting the isoDGR damage motif in lung tissue can guide immune clearance of harmful damaged proteins in vivo, effectively reducing age-linked lung inflammation. We observed age-dependent accumulation of the isoDGR motif in human lung tissues, as well as an 8-fold increase in isoDGR-damaged proteins in lung fibrotic tissues compared with healthy tissue. This increase was accompanied by marked infiltration of CD68+/CD11b + macrophages, consistent with a role for isoDGR in promoting chronic inflammation. We therefore assessed isoDGR function in mice that were either naturally aged or lacked the isoDGR repair enzyme. IsoDGR-protein accumulation in mouse lung tissue was strongly correlated with chronic inflammation, pulmonary edema, and hypoxemia. This accumulation also induced mitochondrial and ribosomal dysfunction, in addition to features of cellular senescence, thereby contributing to progressive lung damage over time. Importantly, treatment with anti-isoDGR antibody was able to reduce these molecular features of disease and significantly reduced lung pathology in vivo.
BibTeX
@inproceedings{kalailingam2025immunotherapeutic,
  author = {Pazhanichamy Kalailingam and SoFong Cam Ngan and Ranjith Iyappan and Afra Nehchiri and Khalilatul‐Hanisah Mohd‐Kahliab and Benjamin Sian Teck Lee and Bhargy Sharma and Radek Macháň and Sint Thida Bo and Emma S. Chambers and Val A. Fajardo and Rebecca E. K. MacPherson and Jian Liu and Panagiota Klentrou and Evangelia Tsiani and Kah‐Leong Lim and I-hsin Su and Yong‐Gui Gao and A. Mark Richar and Raj N. Kalaria and Christopher Chen and Cynthia Balion and Dominique P.V. de Kleijn and Neil E. McCarthy and Siu Kwan Sze},
  title = {{Immunotherapeutic targeting of aging‐associated isoDGR motif in chronic lung inflammation}},
  booktitle = {Aging},
  year = {2025},
  doi = {10.1111/acel.14425},
}
Figure